Zenosense, Inc. (ZENO) Technologies to Address Key Public Health Concerns
Zenosense is primarily focused on addressing unmet medical needs pertaining to bacterial infections and cancer. Leveraging a collaboration agreement with Sgenia Group subsidiary Zenon Biosystem, Zenosense is developing and plans to market two early detection devices, one for Methicillin-resistant Staphylococcus aureus (MRSA) and one for lung cancer.
MRSA-infected patients are likely to spend three times as long in a hospital, costing the United States’ healthcare system approximately $3.2 billion to $4.2 billion annually. MRSA-infected patients are also five times more likely to die than an uninfected patient, which further emphasizes the drastic need for early detection of hospital acquired infections (HAIs) such as MRSA. Though studies suggest that prevention practices have the potential to slash certain HAIs by up to 70%, there is currently no cost effective early detection device on the market.
Zenon Biosystem recently entered into a collaboration agreement with a university and large university hospital in Madrid, Spain, for a lung cancer detection trial involving breath samples from 400 people. The nine-month trial aims to identify VOCs in exhaled breath using standard lab instruments and techniques alongside two identical pre-commercial lung cancer devices that have been developed by Zenon to determine the relative efficacy of Zenon’s devices.
The Zenosense detection devices utilize a common electronic nose technology platform that analyzes volatile organic compounds (VOCs) found in the exhaled breath of patients and scans for certain biomarkers that indicate the presence of infection or illness before a patient demonstrates any obvious symptoms. The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals as well as placed in numerous sensitive areas in the healthcare setting.
Once developed, Zenosense’s cost-effective detection devices are expected to cater to a large, high-demand market driven by patient safety, cost and insurance considerations.
For more information, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Zenosense is primarily focused on addressing unmet medical needs pertaining to bacterial infections and cancer. Leveraging a collaboration agreement with Sgenia Group subsidiary Zenon Biosystem, Zenosense is developing and plans to market two early detection devices, one for Methicillin-resistant Staphylococcus aureus (MRSA) and one for lung cancer.
MRSA-infected patients are likely to spend three times as long in a hospital, costing the United States’ healthcare system approximately $3.2 billion to $4.2 billion annually. MRSA-infected patients are also five times more likely to die than an uninfected patient, which further emphasizes the drastic need for early detection of hospital acquired infections (HAIs) such as MRSA. Though studies suggest that prevention practices have the potential to slash certain HAIs by up to 70%, there is currently no cost effective early detection device on the market.
Zenon Biosystem recently entered into a collaboration agreement with a university and large university hospital in Madrid, Spain, for a lung cancer detection trial involving breath samples from 400 people. The nine-month trial aims to identify VOCs in exhaled breath using standard lab instruments and techniques alongside two identical pre-commercial lung cancer devices that have been developed by Zenon to determine the relative efficacy of Zenon’s devices.
The Zenosense detection devices utilize a common electronic nose technology platform that analyzes volatile organic compounds (VOCs) found in the exhaled breath of patients and scans for certain biomarkers that indicate the presence of infection or illness before a patient demonstrates any obvious symptoms. The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals as well as placed in numerous sensitive areas in the healthcare setting.
Once developed, Zenosense’s cost-effective detection devices are expected to cater to a large, high-demand market driven by patient safety, cost and insurance considerations.
For more information, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
